Neurelis Engages with Epilepsy Community at Disneyland Event for Awareness and Education

Neurelis Engages with the Epilepsy Community at Disneyland



Neurelis, Inc., a leading neuroscience company, recently took part in the 14th Annual Sofie's Journey Epilepsy Awareness Day and Education Expo, held at the Disneyland Resort. This event stands out as one of the largest gatherings designed specifically for those affected by epilepsy, merging families, care partners, and healthcare professionals alike to exchange valuable information and personal experiences.

The participation of Neurelis at this event underscores its commitment to improving the lives of those impacted by epilepsy through education and awareness. The company is well-known for its innovative product, VALTOCO® (diazepam nasal spray), which is designed as a rapid relief option for managing frequent seizure episodes in patients over two years old.

During the event, Neurelis welcomed several ambassadors who shared their personal journeys with epilepsy. One such ambassador, DeJah, expressed the importance of participating in the EADDL event, stating, "Connecting with the epilepsy community is incredibly meaningful to me. Being able to talk about my experience with VALTOCO has given me confidence to advocate for others in similar situations. Knowing I have effective treatment available offers me security and peace of mind when episodes occur."

Ami, another ambassador and a registered nurse, highlighted the collaborative aspect of their journey. "It’s a privilege to work with Neurelis and tell our story to those facing the challenges of epilepsy. Understanding and addressing these experiences collectively fosters a strong support network for families."

Neurelis hosted two informative presentations at the Expo focused on VALTOCO and its role in managing acute seizure activity. The first presentation featured Dr. Raman Sankar, a distinguished professor of neurology and pediatrics at UCLA, alongside DeJah, who shared insights and answered questions from attendees. This approach reinforced the mission of Neurelis, emphasizing the importance of patient voices and experiences.

The second session showcased Dr. Steve Chung from the University of Arizona College of Medicine – Phoenix. Along with ambassador Ami, they provided insights into the utility of VALTOCO, reinforcing its significance as an instantiation of effective epilepsy management.

The event took place from November 16-17, offering attendees a chance not only to learn about epilepsy but also to enjoy family activities at Disneyland. The culmination of the event included a celebratory dance party, embodying the spirit of community and togetherness that defines the EADDL.

Neurelis's CEO, Craig Chambliss, emphasized the value of engaging with the epilepsy community. “Listening to the stories of those affected by epilepsy is crucial for advancing our mission to empower individuals in managing their condition. Opportunities like EADDL allow us to connect and collaborate towards enhancing our collective understanding of epilepsy.”

With a focus on education, Neurelis aims to bridge gaps in awareness and accessibility to effective treatments for families affected by epilepsy. As they continue to innovate, the company's commitment to this community remains strong, further driven by personal narratives of those who live with epilepsy every day.

For more information on Neurelis and VALTOCO, please visit valtoco.com.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.